Subscribe
shutterstock_1625917948_nitpicker
nitpicker / Shutterstock.com
11 October 2021Big Pharma

English High Court finds Bayer patent obvious in win for Teva

The English High Court has found that a challenged claim of Bayer's targeted cancer drug sorafenib is invalid due to obviousness, in a win for Israeli pharmaceutical company Teva Pharmaceuticals.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
Fed Circ panel reviews $235m GSK award over ‘skinny’ Teva generic
25 February 2021   A panel of the US Court of Appeals for the Federal Circuit has considered for a second time the $235 million award to GlaxoSmithKline after Teva Pharmaceuticals was found to have infringed its Coreg heart drug.
Americas
Biogen sues Teva over MS generic
18 March 2021   A proposed Teva Pharmaceutical generic drug to treat multiple sclerosis infringes patents relating to Vumerity, according to a lawsuit filed by Biogen and Alkermes.
Plant Varieties
Rival sues Monsanto, Bayer over GM plant tech
11 August 2022   Firms accused of using GM tech for herbicide-resistant plants | Plaintiff says its patented tech helps farmers to innovate | US District Court for the District of Delaware.


Editor's picks

Americas
UPC bans Meril Life Sciences from selling infringing heart valve
19 November 2024

Editor's picks

Americas
UPC bans Meril Life Sciences from selling infringing heart valve
19 November 2024
Americas
Big Pharma counsel embrace AI but data and legal risks loom
24 October 2024
Asia
President Xi sends message to AIPPI’s World Congress
22 October 2024
Unified Patent Court
‘Every CMS filing is painful’: Notes from a Unified Patent Court dispute
26 September 2024
Unified Patent Court
Interview: Klaus Grabinski, UPC Court of Appeal president
24 September 2024
Unified Patent Court
‘Be prepared, and don’t assume at the UPC’: Christopher Stothers
12 September 2024

More on this story

Americas
Fed Circ panel reviews $235m GSK award over ‘skinny’ Teva generic
25 February 2021   A panel of the US Court of Appeals for the Federal Circuit has considered for a second time the $235 million award to GlaxoSmithKline after Teva Pharmaceuticals was found to have infringed its Coreg heart drug.
Americas
Biogen sues Teva over MS generic
18 March 2021   A proposed Teva Pharmaceutical generic drug to treat multiple sclerosis infringes patents relating to Vumerity, according to a lawsuit filed by Biogen and Alkermes.
Plant Varieties
Rival sues Monsanto, Bayer over GM plant tech
11 August 2022   Firms accused of using GM tech for herbicide-resistant plants | Plaintiff says its patented tech helps farmers to innovate | US District Court for the District of Delaware.

More on this story

Americas
Fed Circ panel reviews $235m GSK award over ‘skinny’ Teva generic
25 February 2021   A panel of the US Court of Appeals for the Federal Circuit has considered for a second time the $235 million award to GlaxoSmithKline after Teva Pharmaceuticals was found to have infringed its Coreg heart drug.
Americas
Biogen sues Teva over MS generic
18 March 2021   A proposed Teva Pharmaceutical generic drug to treat multiple sclerosis infringes patents relating to Vumerity, according to a lawsuit filed by Biogen and Alkermes.
Plant Varieties
Rival sues Monsanto, Bayer over GM plant tech
11 August 2022   Firms accused of using GM tech for herbicide-resistant plants | Plaintiff says its patented tech helps farmers to innovate | US District Court for the District of Delaware.

More features

Bayer gains exclusive licence for heart drug in Japan
EPO delivers key Novo Nordisk, GSK and Inhibrx rulings
McGuireWoods expands team with ex-Novo Nordisk GC
Paul, Weiss swoops for senior duo from Weil, Gotshal
UPC bans Meril Life Sciences from selling infringing heart valve
SCOTUS denies Alvogen unit's appeal to sell Bausch Xifaxan generic
Kathi Vidal to rejoin previous firm as partner following USPTO departure
GSK triumphs in EPO appeal, revoking Pfizer patent